Patent Pack (PDFs)
Research new robot inventions
Patent Pack (PDFs)
Research the latest gaming inventions
Patent Pack (PDFs)
Research new Social Network inventions
Patent Pack (PDFs)
Research new Drone inventions
Patent Pack (PDFs)
Research the latest Electric Vehicle inventions
Patent Pack (PDFs)
Research latest Smartphone inventions
Patent Pack (PDFs)
Research new robot inventions
Patent Pack (PDFs)
Research the latest gaming inventions
Patent Pack (PDFs)
Research new Social Network inventions
Patent Pack (PDFs)
Research new Drone inventions
Patent Pack (PDFs)
Research the latest Electric Vehicle inventions
Patent Pack (PDFs)
Research latest Smartphone inventions
Glaxo Group Limited |
Glaxo Group Limited A Corporation |
Ligands that bind tgf-beta receptor ii
The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure... Glaxo Group Limited
Methods for selecting protease resistant polypeptides
The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing... Glaxo Group Limited
The invention relates to non-aqueous dentrfrice compositions comprising a surfactant system. The surfactant system consists of a combination of surfactants i.e. a betaine and a taurate surfactant; or a betaine and an alkyl sulphate surfactant; or a betaine, a taurate and an alkyl sulphate surfactant.... Glaxo Group Limited
Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.... Glaxo Group Limited
Positive allosteric modulators of human melanocortin-4 receptor
Disclosed herein are positive allosteric modulators of melanocortin receptor and methods of using such modulators.... Glaxo Group Limited
Anti-serum albumin binding variants
The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.... Glaxo Group Limited
2 substituted cephem compounds
The compounds of the subject invention are related to 2-substituted cephem compounds, which have a wide antimicrobial spectrum, in particular exhibit potent antimicrobial activity against beta-lactamase producing Gram negative bacteria, and pharmaceutical compositions comprising the same.... Glaxo Group Limited
Process for separation of oligonucleotide of interest from a mixture
A method for separation of an oligonucleotide from a mixture using a biphasic mobile phase/stationary phase liquid-liquid chromatography system. A first mobile phase contains the oligonucleotide and the stationary phase contains an exchanger substance that removably binds to the target oligonucleotide. The mobile phase is caused to flow in contact... Glaxo Group Limited
An inhalation device having at least one elongate medicament carrier including, but not limited to, a pair of sheets sealed together and a plurality of medicament powder doses positioned at spaced-apart locations between said sealed sheets, an outlet for a user to inhale from, and a mechanism for stepwise advancement... Glaxo Group Limited
Novel milk beverage composition comprising creatine
Ready to drink milk beverage compositions are described comprising creatine and an added protein such as whey protein, which have good creatine shelf life at ambient temperatures.... Glaxo Group Limited
and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.... Glaxo Group Limited
Antigen binding proteins to oncostatin m (osm)
The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further... Glaxo Group Limited
2- (azaindol-2-yl) benzimidazoles as pad4 inhibitors
and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.... Glaxo Group Limited
A package which can be torn open by a user, comprising a polymer film material having a preferential tearing direction and defining a cavity for a product, wherein the polymer film material incorporates a bias facilitating tearing along a tear line oriented in a direction other than its preferential tearing... Glaxo Group Limited
The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ.... Glaxo Group Limited
The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising... Glaxo Group Limited
The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.... Glaxo Group Limited
The invention is directed to certain novel compounds. Specifically, crystalline forms of N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide and crystalline 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole, along with salts thereof.... Glaxo Group Limited